. [eighty two] to assess the efficacy, safety and tolerability of Cannabidiol as an adjunct therapy coupled with anti-epileptic medications around the sufferers struggling from tuberous sclerosis advanced whose most frequent neurological symptom is epilepsy. With this medical demo review, just a